1. Home
  2. FA vs STOK Comparison

FA vs STOK Comparison

Compare FA & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Advantage Corporation

FA

First Advantage Corporation

HOLD

Current Price

$12.37

Market Cap

2.3B

ML Signal

HOLD

Logo Stoke Therapeutics Inc.

STOK

Stoke Therapeutics Inc.

HOLD

Current Price

$33.49

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FA
STOK
Founded
2003
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.0B
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
FA
STOK
Price
$12.37
$33.49
Analyst Decision
Buy
Strong Buy
Analyst Count
4
10
Target Price
$15.67
$39.20
AVG Volume (30 Days)
914.0K
648.1K
Earning Date
05-07-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
72.97
92.73
EPS
N/A
N/A
Revenue
$1,574,389,000.00
$184,420,000.00
Revenue This Year
$8.42
N/A
Revenue Next Year
$7.26
$77.49
P/E Ratio
N/A
N/A
Revenue Growth
83.02
404.50
52 Week Low
$8.82
$8.30
52 Week High
$19.01
$40.22

Technical Indicators

Market Signals
Indicator
FA
STOK
Relative Strength Index (RSI) 55.77 45.21
Support Level $12.10 $32.70
Resistance Level $12.78 $35.06
Average True Range (ATR) 0.58 1.60
MACD 0.10 -0.06
Stochastic Oscillator 57.29 31.16

Price Performance

Historical Comparison
FA
STOK

About FA First Advantage Corporation

First Advantage Corp is a provider of software and data in the Human Resources technology industry. The company provides end-to-end identity solutions, criminal background screening, credential verifications, drug and health screening, and continuous risk monitoring. It combines AI-powered proprietary technology platforms with proprietary data, primary source data, and third-party data. Its reportable segments are First Advantage Americas, First Advantage International, and Sterling. The company generates maximum revenue from the Sterling segment, which provides similar services as compared to First Advantage's Americas and International segments on a global basis. Geographically, the company generates the majority of its revenue from the United States.

About STOK Stoke Therapeutics Inc.

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Share on Social Networks: